Revumenib

CHEMBL4650827 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

630.8 g/mol

LogP

4.3

Phase

4

Revumenib is a potent, selective menin inhibitor that disrupts the interaction between the menin protein and KMT2A (MLL1) fusion oncoproteins, restoring normal differentiation programs in leukemic cells by abrogating aberrant transcriptional activation of HOXA genes and MEIS1. It is approved for relapsed or refractory acute leukemia with KMT2A translocation and is under investigation in NPM1-mutant AML and other menin-dependent malignancies.

Molekularmasse

630,8000 g/mol

LogP

4,30

TPSA

116,00 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C

InChI

InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3/t24-,26-

Molecular Formula

C32H47FN6O4S

HBD / HBA

1 / 10

Rotierbare Bindungen

11

Schwere Atome

44

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Revumenib is a potent, selective menin inhibitor that disrupts the interaction between the menin protein and KMT2A (MLL1) fusion oncoproteins, restoring normal differentiation programs in leukemic cells by abrogating aberrant transcriptional activation of HOXA genes and MEIS1. It is approved for relapsed or refractory acute leukemia with KMT2A translocation and is under investigation in NPM1-mutant AML and other menin-dependent malignancies.

Yes, Revumenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650827. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 132212657. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Revumenib auf PillFYI

Struktur

Schnelldaten

Formel: C32H47FN6O4S
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.